Stay updated on Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial

Sign up to get notified when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Added 'Gastric cancer' as a keyword and included the Genetic and Rare Diseases Information Center under Resources. Page revision updated from v3.4.1 to v3.4.2.
    Difference
    0.2%
    Check dated 2026-02-13T12:35:09.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A minor page revision tag was added: Revision: v3.4.1, updating from v3.4.0, with no changes to study content or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-05T23:40:55.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Revision tag updated from v3.3.3 to v3.3.4. No substantive changes to the study details page are evident.
    Difference
    0.1%
    Check dated 2026-01-15T03:53:52.000Z thumbnail image
  5. Check
    62 days ago
    Change Detected
    Summary
    Added a Locations section listing Massachusetts, New York, and Pennsylvania as study sites; standalone entries for Massachusetts Locations, New York Locations, and Pennsylvania Locations were removed. Updated the page to revision v3.3.3 and removed the HHS Vulnerability Disclosure link.
    Difference
    0.4%
    Check dated 2025-12-24T13:51:46.000Z thumbnail image
  6. Check
    91 days ago
    Change Detected
    Summary
    Site revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T13:35:31.000Z thumbnail image
  7. Check
    99 days ago
    Change Detected
    Summary
    Removed the government funding status notice from the page. All study details, eligibility criteria, locations, and study plan remain unchanged.
    Difference
    0.4%
    Check dated 2025-11-18T07:19:45.000Z thumbnail image

Stay in the know with updates to Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.